A Study of the Value of p53, HER2, and Bcl-2 in the Prediction of Response to Doxorubicin and Paclitaxel as Single Agents in Metastatic Breast Cancer: A Companion Study to EORTC 10923.
Hamilton, A. 1; Larsimont, D. 2; Paridaens, R. 3; Drijkoningen, M. 3; van de Vijver, M. 4; Bruning, P. 4; Hanby, A. 5; Houston, S. 5; Treilleux, I. 6; Guastalla, J. P. 6; Van Vreckem, A. 1; Sylvester, R. 7; Piccart, M. 2
[Miscellaneous] Clinical Breast Cancer. 1(3):233-240, October 2000.

(Format: HTML, PDF)

: This study assesses the potential value of the tumor markers p53, HER2, and Bcl-2 in predicting the clinical response to doxorubicin and paclitaxel as single agents in the treatment of metastatic breast cancer. The primary tumors of 114 patients in the European Organization for Research and Treatment of Cancer 10923 trial were assessed by immunohistochemistry using monoclonal antibodies; the results were correlated with clinical response to therapy. HER2 was positive in 24% of patients, p53 was positive in 25% of patients, and Bcl-2 was positive in 49% of patients. There was no correlation between the expression of any of the markers and the clinical response to either agent. Although methodologically limited, this study does not support the use of p53, HER2, or Bcl-2 to assist the selection of anthracycline versus taxane in metastatic breast cancer.

Clinical Breast Cancer, Vol. 1, No. 3, 233-240, 2000

(C) 2000 CIG Media Group, lp.